{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgJ6boskKDA","lastupdate":"2022-11-16T00:00:00.000Z","update_date":"2022-11-16T00:00:00.000Z","lastModified":"Aug 12, 2025","active":1,"confidence_score":100,"confidence_score_reason":"markets","urlname":"bonus-biogroup","minimal_profile":null,"status":"Public","fullstatus":"Public on TASE on Feb, 2012<br>","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$jMMfmIzlohFeW1U54Fj6ANul5oWkmryUpVqntHKkYKwX8r9hGsKwKJ","name":"Bonus BioGroup","oneliner":"Viable Tissue-regenerating Bone Grafts","registrar":"520039777","website":"https://www.bonus-bio.com","careerspage":"","founded_month":10,"founded_year":1981,"formernames":[],"sociallinks":{"twitter":"https://twitter.com/BBiogroup","youtube":"https://www.youtube.com/channel/UChXNkBN4lQ0QKLW1w1Dls_Q","facebook":"https://www.facebook.com/BonusBio","linkedin":"https://www.linkedin.com/company/14822062","instagram":""},"social":["https://twitter.com/BBiogroup","https://www.linkedin.com/company/14822062","https://www.facebook.com/BonusBio","https://www.youtube.com/channel/UChXNkBN4lQ0QKLW1w1Dls_Q"],"flattenedsociallinks":"https://twitter.com/BBiogroup|https://www.linkedin.com/company/14822062|https://www.facebook.com/BonusBio|https://www.youtube.com/channel/UChXNkBN4lQ0QKLW1w1Dls_Q","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":1,"employees":"11-50","employees_exact":41,"patent":1,"raised":25600000,"stage":"Public","public_stage":"Public","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":["Bonus Bio-Group","Waze Pharma","Bonus Bio Group"],"about":"Bonus BioGroup is a product-focused biotechnology company applying proprietary technology to supply tissue-regenerating, viable bone grafts. The company develops cell therapy and tissue-engineering products based on autologous bone implants that enable efficient bone transplantation and provide cell-based bone replacement for repairing bone lesions.\r\n\r\nBonus BioGroup is the developer of BonoFill, a method for growing high-density 3D bone grafts based on multicell 3D cultures. BonoFill is derived from the patients own cells and constructed from a variety of cells grown in multiple layers within a bioreactor system.\r\n\r\nBonoFills technology enables the construction of bone grafts outside of the human body (ex vivo) and promotes graft acceptance by the patients body following transplantation. It also allows growth of a human tissue graft tailored to the biological, physical, and clinical needs of each patient, without incurring immune reactions or graft rejection.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"+972732067104","country":null,"address":{"israeli":[{"id":"23bc8f7d-b55f-4069-82e5-bd8dd7fcb619","city":"Haifa","type":null,"address":"Nahum Het St 9, Haifa, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":null},"headquarter_address":null,"district":"North District","news":[{"id":"CoKSVm1FanodmTKAoBJYXnEVrZC1I2Gua3u1odXwxm1n2ymYNSxlcC","date":"Sep 9, 2025","link":"https://finance.yahoo.com/news/strauss-group-tase-strs-assessing-130928825.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"earnings, valuation","round":null,"company":"Strauss Group","layoffs":null,"summary":"Strauss Group has released its second quarter and half-year earnings, showing a rise in sales for both periods in 2025. Despite the increase in revenue, net income has decreased, indicating potential cost pressures or margin changes. The companys stock has risen by nearly 64% over the past year, though recent gains have slowed. Strauss Groups price-to-earnings ratio is slightly below the Asian Food industry average, suggesting it is valued in line with sector peers. The companys strong profit growth and above-average profit margin support its current valuation. However, potential risks include slowing net income growth or changes in consumer demand.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["earnings","valuation","growth","stock","margins"],"date_of_event":"2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"FOZdAK6ROAG4u2tulcNw5K1hzuE3yeTq79m5eIRi8DnmveFkjSAu0V","news_summary":"Strauss Group (TASE:STRS): Assessing Valuation After Mixed Q2 Earnings and Sales Growth","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"i593rRbWNDThGlhqRE2CCnkRvIqxLFy33B1Yb4uBaQuz6Dm9y9uZ3D","date":"Sep 9, 2025","link":"https://finance.yahoo.com/news/nikkiso-addresses-growing-ammonia-handling-060000400.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"innovation","round":null,"company":"Nikkiso Clean Energy & Industrial Gases Group","layoffs":null,"summary":"Nikkiso Clean Energy & Industrial Gases Group (Nikkiso CE&IG) announced the launch of a next-generation submerged ammonia pump at the Gastech Conference. This pump is designed to be the safest and most reliable in the industry, addressing common maintenance issues with its seal-less, maintenance-friendly, copper-free construction. The pump can deliver over 2,500m3 per hour and has a mean time between outages of over 16,000 hours. This launch is part of Nikkiso CE&IGs ongoing innovation in ammonia handling, with the company having decades of experience in this field. The pump is expected to meet growing demand for ammonia in various sectors, including power generation and shipping.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["ammonia","pump","innovation","hydrogen","safety"],"date_of_event":"September 09, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"2VNok2g511DpuYCdEJvslzcKzPSMNP5dIzmgMLw61kbxPaAtllRFpu","news_summary":"Nikkiso Addresses Growing Ammonia-Handling Demand and Launches Next-Generation Pump at Gastech 2025","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"88obO9LBoLtfZIqeyT0IjR5BSjPtQKq9ghbH3oG3DU4Uf4WEwKUthg","date":"Sep 9, 2025","link":"https://www.hotelmanagement-network.com/news/westin-desaru-coast-cayin-technology/","source":"www.hotelmanagement-network.com","visible":1,"analysis":{"tags":"partnership","round":null,"company":"CAYIN Technology","layoffs":null,"summary":"CAYIN Technology has partnered with Westin Desaru Coast Resort in Johor, Malaysia, to enhance guest communication and operational efficiency through the implementation of its CMS-WS server and CAYIN Signage Player. This collaboration involves the use of digital signage to provide real-time updates across 14 Samsung displays in various areas of the resort. The project was executed in partnership with Hola Media, which provided integration services, including installation, design, staff training, and support. The system has improved communication, reduced staff workload, and enhanced the guest experience, preparing the resort for future digital expansion.","partners":"Hola Media","customers":"Westin Desaru Coast Resort","eventType":null,"investors":null,"confidence":9,"key_topics":["partnership","digital signage","hospitality","operational efficiency","guest communication"],"date_of_event":"September 9, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"k5Yj1huWVlFrfm2vyUbW5Xdii8HGJfFMOA5dQmWEoZWmWtAWB7WTfO","news_summary":"Westin Desaru Coast Resort partners with CAYIN Technology for digital signage","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"eGYcr9roaaDjzLfeq916KkBOoU7Cb0q5Gw725rlkaHPSAziBlEY2M8","date":"Sep 9, 2025","link":"https://finance.yahoo.com/news/bhp-xplor-opens-applications-2026-051100065.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"accelerator program","round":null,"company":"BHP Group Limited","layoffs":null,"summary":"BHP Group Limited has announced the opening of applications for the 2026 cohort of its BHP Xplor accelerator program, which aims to transform the discovery of critical minerals. The program offers early-stage explorers up to USD $500,000 in equity-free funding, mentorship, and access to BHP’s global network. BHP Xplor has been successful in previous years, fostering partnerships and accelerating exploration projects. The program supports BHPs long-term growth by engaging with diverse exploration projects. Applications are open from September 8 to October 15, 2025.","partners":["Electrum Discovery"],"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["accelerator","exploration","minerals","funding","partnerships"],"date_of_event":"September 09, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"500,000","structured_issues":["Partners"],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"JU8P5WAWgywLCNf6WRA537oGJ45YAIaSNJhWMadaGJs4wVk18MzFth","news_summary":"BHP Xplor Opens Applications for 2026 Cohort, Offering Equity-Free Funding and Global Support","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"hMvMwOFy6U1mRSFhiOt502xNLDBchBMhWZFrVl6UgeCwb5cfhs3sFJ","date":"Sep 9, 2025","link":"https://sg.finance.yahoo.com/news/indian-stock-benchmarks-likely-open-023120091.html","source":"sg.finance.yahoo.com","visible":1,"analysis":{"tags":"share buyback","round":null,"company":"Infosys","layoffs":null,"summary":"Infosys led gains in Indias Nifty 50 index, which closed higher for the fifth consecutive session, driven by a 5% surge in Infosys shares following the announcement of a share buyback plan. The IT sector, which accounted for a significant portion of the days gains, benefited from expectations of a U.S. interest rate cut, which could boost technology spending in the U.S., a key market for Indian IT firms. The broader market also saw gains, with the Nifty 50 and BSE Sensex both rising by 0.39%. The anticipation of a Federal Reserve rate cut was fueled by weaker-than-expected U.S. job data.","partners":[],"customers":[],"eventType":null,"investors":[],"confidence":9,"key_topics":["Infosys","share buyback","IT stocks","U.S. rates","Nifty gains"],"date_of_event":"September 11","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"1rUiMkoKgpirdBPEjSGBxu0ebH5dLfoByYIpCDWEAdYVO5Xz61bcuc","news_summary":"Nifty clocks fifth session of gains led by IT on  Infosys buyback, US rate cut hopes","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"ZaKevRGUr5A4shHxVQYDsRhNaA7olilk0PPJ2rEA0noDK3FWy1lQtx","date":"Aug 7, 2025","link":"https://finance.yahoo.com/news/middle-eastern-penny-stocks-market-040501959.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"financial performance","round":null,"company":"Bank Of Sharjah P.J.S.C.","layoffs":null,"summary":"The article discusses the performance of Middle Eastern stock markets, highlighting the mixed results in Gulf equities and record highs in Egypt. It focuses on penny stocks, including Bank Of Sharjah P.J.S.C., which operates in commercial and investment banking in the UAE. Despite challenges like high bad loans and low return on equity, the company has shown impressive earnings growth, with net income surging by 1067.8% over the past year. The companys revenue is primarily from its Commercial Banking and Investment and Treasury segments. Recent earnings reports indicate strong net interest income growth, suggesting potential for continued financial improvement.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["stock market","earnings growth","financial health","investment banking","volatility"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"8lqdRMNNpG4VEZS2vgSZ1xIbTI06KZeRGb7q4HDeLfnUVGm9Sa4X86","news_summary":"Middle Eastern Penny Stocks With Market Caps Over US$80M","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"NO6sl6y6dDoif5FHW9vUUNyrKt25A2flxbexLB3REUtlptcY5PlZJe","date":"Jul 14, 2025","link":"https://finance.yahoo.com/news/bonus-biogroup-appoints-renowned-cell-110000507.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"leadership, clinical trials","round":null,"company":"Bonus Biogroup","layoffs":null,"summary":"Bonus Biogroup, a biotechnology company focused on tissue engineering and cell therapy solutions, has appointed Professor Edwin M. Horwitz to its Advisory Board. This strategic move aims to strengthen the companys leadership as it progresses toward Phase 3 clinical trials for its therapies BonoFill and MesenCure. Prof. Horwitz, a renowned expert in cell therapy, brings extensive experience in MSC biology and clinical application. His appointment underscores Bonus Biogroups commitment to advancing the field of regenerative medicine through scientific excellence and innovation. The company is poised to deliver transformative cell therapies to address urgent unmet medical needs.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["leadership","clinical trials","stem cells","regenerative medicine","cell therapy"],"date_of_event":"July 14, 2025","product_stage":"Phase 3","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Management Changes"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage  #Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"0oRcIS5HjGjDueHfkCt1lBW95i6u5XhLcf124G5CHU51hVQBoYfhwb","news_summary":"Bonus Biogroup Appoints Renowned Cell Therapy Leader, Professor Edwin M. Horwitz, MD, PhD, to its Advisory Board","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"F7UuYNjmQkWw4wZ66dyZlFmVEYW6OfpwXAGYri7F455JvMp5FtCsT5","date":"Jul 9, 2025","link":"https://finance.yahoo.com/news/middle-eastern-penny-stocks-watch-040504583.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"investment, growth","round":null,"company":"Amanat Holdings PJSC","layoffs":null,"summary":"Amanat Holdings PJSC, with a market cap of AED2.71 billion, has shown significant earnings growth of 166.2% over the past year, surpassing both its five-year average and industry growth rates. The company invests in education and healthcare sectors, with revenues from these segments amounting to AED460.94 million and AED362.38 million, respectively. Despite a low return on equity of 6% and a dividend yield of 4.22% not well covered by free cash flows, the companys debt level is manageable, with operating cash flow covering it well. Recent Q1 results showed increased sales but a slight dip in net income compared to last year.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["Gulf stocks","penny stocks","financial health","market dynamics","investment profile"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":"AED2.71 billion","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"VJcoQt85Hg4NBMnIvfVAKZ9Q6WPSSnnPzF2qMIn89Laqh4XUm80tUU","news_summary":"Middle Eastern Penny Stocks To Watch In July 2025","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"ILEhctkmG42LBE2aPzV3YREN4mnfTo1rAUdsjRSDUfbRyJBQe4CJ7I","date":"Jun 10, 2025","link":"https://finance.yahoo.com/news/middle-eastern-penny-stocks-watch-090510028.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"financial performance","round":null,"company":"Bank Of Sharjah P.J.S.C.","layoffs":null,"summary":"Bank Of Sharjah P.J.S.C. has shown a significant improvement in profitability, with net income rising to AED 116.35 million for Q1 2025, up from AED 80.67 million the previous year. This growth is supported by a one-off gain of AED101.9M. The banks financial structure is robust, primarily backed by low-risk customer deposits, which account for 82% of its liabilities. However, the bank faces challenges such as a high level of non-performing loans at 7.6% and an inexperienced management team with an average tenure of just 0.5 years. Despite these challenges, the banks financial health is rated positively, indicating a growth-positive outlook.","partners":[],"customers":[],"eventType":null,"investors":[],"confidence":9,"key_topics":["profitability","market cap","non-performing loans","management","deposits"],"date_of_event":"Q1 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":"AED2.58B","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"KzvEvlkcUN30Rj93azYeC1iHlVRm9qYrNjkETnvRtZmy7Mm6ulMKx4","news_summary":"Middle Eastern Penny Stocks To Watch In June 2025","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"u4g1tJCm7NXUz9oicBElBbhKfwuKD2gPdLUiyN65J6Y3gUBsu8m3OF","date":"May 12, 2025","link":"https://finance.yahoo.com/news/middle-eastern-penny-stocks-market-040451959.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"financial health","round":null,"company":"Ihlas Yayin Holding A.S.","layoffs":null,"summary":"Ihlas Yayin Holding A.S., a Turkish company operating in media, publishing, and advertising, is highlighted in the context of Middle Eastern penny stocks. Despite having a market cap of TRY940.50 million and generating revenue from various segments, the company faces financial challenges. Its revenue of TRY2.48 billion shows a slight decline, and it remains unprofitable with a net loss of TRY227.23 million. However, the company has more cash than debt, and its short-term assets exceed liabilities, indicating some financial resilience. The boards average tenure of 5.3 years suggests experienced governance, but the companys cash runway is less than a year if free cash flow continues to shrink. This mixed financial landscape presents both risks and opportunities for investors.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["penny stocks","financial health","market cap","revenue decline","cash runway"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"3DhHBKHn6E5xAqSYFdv6iz3q7ontIrAIHfvYZzbw8E2kCINSdSgP6U","news_summary":"Middle Eastern Penny Stocks With Market Caps Over US$60M To Watch","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"XA8iau0im5YDpQha7k5EDNp2rPOkXmGZ4TFQMvWjnojqf0PMZqWdnM","date":"Mar 10, 2025","link":"https://finance.yahoo.com/news/discover-middle-eastern-penny-stocks-030447025.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"financial health","round":null,"company":"Dubai National Insurance & Reinsurance (P.S.C.)","layoffs":null,"summary":"The article discusses the performance of Middle Eastern stock markets, with a focus on penny stocks, including Dubai National Insurance & Reinsurance (P.S.C.). Despite having no debt and a market cap of AED431.97 million, the company faces challenges due to declining earnings, which have decreased by 6.5% annually over the past five years. The companys financial stability is highlighted by its ability to cover liabilities with short-term assets, yet its return on equity is low at 5.7%. The article suggests that while the company has high-quality earnings and an attractive price-to-earnings ratio, its recent negative growth complicates its investment outlook.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["stock market","penny stocks","financial health","market cap","earnings"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"0fS2N9XDJmjgqHgMc4qcfixWyVo0FAtUsFqYrkrtywwdFzS17xeAze","news_summary":"Discover Middle Eastern Penny Stocks: Dubai National Insurance & Reinsurance (P.S.C.) And 2 More Hidden Opportunities","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"t5vDyFlNxwsxcxhVdXdJ3tgh9dyCA0tFJU32HHCFa7ZOwQxHjrQ2FE","date":"Feb 20, 2025","link":"https://finance.yahoo.com/news/bonus-biogroup-announces-u-food-130000774.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"FDA clearance","round":null,"company":"Bonus Biogroup","layoffs":null,"summary":"Bonus Biogroup, a biotechnology company, has received FDA clearance to proceed with a Phase III clinical study in the United States for its cell therapy product, MesenCure. This therapy is designed to treat respiratory distress in severely ill patients, including those with COVID-19-related pneumonia. The company aims to expand the study to include acute respiratory distress syndrome (ARDS) from any cause. Previous Phase II studies showed significant reductions in mortality and the need for invasive ventilation. This FDA clearance marks a significant milestone for Bonus Biogroup, highlighting their research and innovation in cell therapy.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["FDA clearance","Phase III","MesenCure","ARDS","COVID-19"],"date_of_event":"February 20, 2025","product_stage":"Phase III","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"using","structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"yzbrm5rRAt7fFVWC9XkPacadHncoqW3Qbu3J1Vc5pUjdTNPsHbIMKV","news_summary":"Bonus Biogroup Announces U.S. Food and Drug Administration (FDA) Clearance of an Investigational New Drug (IND) Application for MesenCure™ Phase III Clinical Study in Respiratory Distress","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"G9NhJW7WeJsaDNNcmEcJz5zEJVDP03ju8Ijv22lVPsXgu0s9YgsCAA","date":"Feb 6, 2025","link":"https://finance.yahoo.com/news/february-2025s-promising-penny-stocks-080652508.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"penny stocks","round":null,"company":"V.S. International Group Limited","layoffs":null,"summary":"V.S. International Group Limited, an investment holding company specializing in plastic molded products, is spotlighted for its financial health and potential growth in the penny stocks market. Despite being currently unprofitable, the company has managed to reduce its losses by 35.2% annually over the past five years. It maintains a satisfactory net debt to equity ratio and solid liquidity management, with short-term assets exceeding liabilities. The company has extended a Memorandum of Understanding (MOU) with Mega Fortris Berhad, indicating potential strategic growth opportunities in Macaos playing card market, with execution pending until July 2025.","partners":"Mega Fortris Berhad","customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["penny stocks","financial health","market cap","strategic growth","liquidity"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"9BD0MFgIYhooVQt7jhvpUegvrTKyZIgFGyNHjVV6enSbbnYPhJvgP7","news_summary":"February 2025's Promising Penny Stocks For Savvy Investors","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"aO1egUEHVIKOvABVuNAfzIpnqe3CVYAeeS6yCMSAbAthTS15DV3kAS","date":"Jan 2, 2025","link":"https://finance.yahoo.com/news/oriola-oyj-2-other-promising-190752087.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"financial health","round":null,"company":"Oriola Oyj","layoffs":null,"summary":"Oriola Oyj, a company with a market cap of €161.88 million, primarily operates in Sweden and Finland. Despite being unprofitable with a negative return on equity of -3.36%, the company has managed to reduce its debt-to-equity ratio over the past five years and holds more cash than total debt, indicating financial prudence. However, Oriola faces liquidity challenges as its short-term liabilities exceed its assets. Recent management changes, with Satu Nylén and Katja Lundell joining the executive team, could bring a fresh strategic direction. The company is trading below its estimated fair value, and efforts are ongoing to stabilize earnings growth, which is forecasted at 77.63% annually.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["financial health","management changes","earnings forecast","liquidity challenges","market cap"],"date_of_event":"January 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":"€161.88 million","impact_on_company":"growth-negative","investment_amount":null,"structured_issues":["Management Changes"],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"XyfcD9NpQx4OYYwW54DEExgkLZr1okY8kK4cQThvJatbb0yyOaewBG","news_summary":"Oriola Oyj And 2 Other Promising Penny Stocks To Watch","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"fFX58JAWkvQ78o507wkNGXrYmFCFqyU1uDw6hD3dFyB8v1gLnOwqlq","date":"Sep 26, 2024","link":"https://www.sponser.co.il/Article.aspx?_atscid=7_134353_204082920_2704293_0_Txtetaxjxdshwhus8sp&ArticleId=116210","source":"www.sponser.co.il","visible":1,"analysis":null,"sentiment":null,"analysisId":"362HTXyrgTQvKt57ZVVL492g3eIWuli1D3PcT88N4u7N8joHLsilxY","news_summary":"בונוס ביוגרופ מנסה להתאושש: קיבלה אישור פטנט מהשרד האירופי והאנגלי","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"pghYbsdUjkudFWfGQ5T5RLS7nWHj6MvBiAOTWUF1txqcrainft27Vj","date":"Jan 23, 2024","link":"https://itnews.co.il/news/events-expos/?_atscid=7_134353_204082920_2527013_0_Txtetaxjxdshwhus8sp&p=47852","source":"itnews.co.il","visible":1,"analysis":{"tags":"Biotechnology, Innovation","company":"Bonus Biogroup","layoffs":"Not mentioned","summary":"Israeli biotech company, Bonus Biogroup, has been awarded the prestigious Advanced Therapies award in the most important category: Cell Therapy Biotech Innovation. The award recognizes the company as a global leader in biotechnology and cell therapy innovation and the development of effective treatments for patients. The company has two innovative products in advanced clinical trials: MesenCure - a cell therapy for treating inflammation and tissue damage, including lung inflammation and respiratory distress; and BoneFill - a human bone graft for completion, regeneration and construction of bone tissue.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":"Cell Therapy, Biotech Innovation, Clinical Trials, Tissue Engineering","date_of_event":"16-19 January, 2024","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Customers, Partners","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers, Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"IbFYPlYMkjJWrgL9Qbx2cmvqxIAkoYSajGKX3jGPJxsc8tFNAYiI2h","news_summary":"הצלחה היסטורית: לראשונה, זכתה חברה ישראלית בפרס התרפיות המתקדמות בעולם","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"oxxWhiSKGjPiElA8Dxq5GQVd59fynSUzBjob7UFhNYAjj0tWRkNItd","date":"Aug 27, 2023","link":"https://www.sponser.co.il/Article.aspx?_atscid=7_134353_204082920_2462051_0_Txtetaxjxdshwhus8sp&ArticleId=112900","source":"www.sponser.co.il","visible":1,"analysis":{"tags":"Medical Innovation","company":"Bonus Biogroup","layoffs":null,"summary":"Bonus Biogroup, an Israeli biotechnology company, has reported successful results from a phase 2 clinical trial using its lab-grown BonoFill bone graft product for arthrodesis procedures in the foot and ankle. The companys product eliminates the need for autologous bone grafts, which require harvesting bone from the patient. The successful results were presented at the World Orthopedic Congress in London. The company estimates that by 2030, the potential market for its product in the US alone could reach 6.2 million patients per year, representing a market value of approximately $70 billion.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["Bone Graft","Clinical Trial","Orthopedics","Arthrodesis","Market Potential"],"date_of_event":"27.08.2023","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":"Investment","acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"zYX0FP1oMxcOhTsntzSb83fFAGNvHcVPhiyUv2UFoLpyColh4dyFBR","news_summary":"ספונסר תקלה","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"e97966c6-262a-4fb5-8ad8-ae21f6f4b1cc","date":"May 16, 2022","link":"https://www.israel21c.org/israeli-covid-drug-also-aids-cancer-immunotherapy-patients/","source":"www.israel21c.org","visible":1,"analysis":{"tags":"biotechnology, drug development","company":"Bonus BioGroup","layoffs":null,"summary":"Israeli biotechnology company Bonus BioGroup announced that its Covid drug, MesenCure, can also reduce life-threatening inflammatory overreaction in cancer patients treated with immunotherapy. The companys focus has been on cell therapy and tissue engineering for bone tissue regeneration and reconstruction. Bonus BioGroup will continue to develop MesenCure to treat severely ill Covid patients.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Covid drug","inflammatory overreaction","cancer patients","cell therapy","tissue engineering"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"vz4JAbmv1WUMOexAvAnFl8XUpFTajFQNl9wskMVTUrCOS0xKVyzoN8","news_summary":"Israeli Covid drug also aids cancer immunotherapy patients","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"XN4JI6KRLRFaDD8M6QiQTcdrn1emSsPGxurOsZfmdSLpTe9jiKwe50","date":"Jan 17, 2022","link":"https://www.biospace.com/article/bonus-biogroup-submits-outstanding-phase-ii-trial-results-for-mesencure-a-treatment-for-severe-covid-19-to-the-israeli-ministry-of-health/","source":"www.biospace.com","visible":1,"analysis":{"tags":"Clinical Trials, Biotechnology","company":"Bonus BioGroup","layoffs":"N/A","summary":"Bonus BioGroup, an Israeli biotechnology company, has submitted the results of its Phase-II clinical trial to the Israeli Ministry of Health. The trial involved the use of MesenCure, a treatment for severe COVID-19 patients, which demonstrated high levels of efficacy and safety. The treatment was found to significantly reduce mortality rates and duration of hospitalization for severe COVID-19 patients. The company plans to promote the commercialization of MesenCure by pursuing Phase-III clinical trials in Israel and other countries. The company also projects that the hospital cost of treatment can be decreased by an average of 40%, with immediate savings for the healthcare system expected to fall within the range of $30,000-$40,000 per patient.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Clinical Trial Results","COVID-19 Treatment","MesenCure","Hospitalization Reduction","Market Opportunity"],"date_of_event":"January 18, 2022","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Customers","Expand"],"acquisition_amount":"N/A","structuredIssuesShow":"#Customers  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"m1gxj148BCQTjeePTESG8WFIA3A6SKuq0bVbiuy8UXwAUEq8AKOrix","news_summary":"Bonus BioGroup Submits Outstanding Phase-II Trial Results for MesenCure, a Treatment for Severe COVID-19, to the Israeli Ministry of Health | BioSpace","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"7cf31f95-dd38-4fa8-9bda-e3c4c76f42ef","date":"Jan 10, 2022","link":"https://www.globes.co.il/news/article.aspx?_atscid=7_134353_204082920_2085806_0_Txtetaxjxdshwhus8sp&did=1001397932","source":"www.globes.co.il","visible":1,"analysis":{"tags":"Healthcare, Covid-19","company":"בונוס ביוגרופ","layoffs":"Not mentioned","summary":"Israeli biotech company Bonus Biogroup has submitted its drug Mesencure, intended for severe Covid-19 patients, for approval by the Israeli Health Ministry. If approved, it would be the first Israeli drug approved for emergency use in treating Covid-19. The company also intends to seek emergency approval from the European Medicines Agency (EMA) and simultaneously apply for a phase III trial for severe Covid-19 patients in Israel and other countries. The companys main shareholders are founder and CEO Dr. Shai Meretzki (33%) and Chairman Yossi Reich (11%). Recently, venture capital fund SIBF joined the investors in Bonus, holding about 8.3% of the capital.","partners":"Not mentioned","customers":"Not mentioned","investors":"SIBF","confidence":8,"key_topics":"Drug Approval, Covid-19 Treatment, Health Ministry, Clinical Trials, Investment","date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Customers, Investment","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers, Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"bbjrchHmxhteUK8ALlbPEK5J5azMuEohUJ0xFpEjMbjBgBYMuZfSVA","news_summary":"בונוס מבקשת אישור חירום לתרופה לקורונה. האם מ' הבריאות יסכים?","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"c8f7fbcf-6fb1-4fb1-9dfa-033abe0b05ec","date":"Nov 25, 2021","link":"https://www.israel21c.org/drug-saves-47-of-50-severe-covid-patients-in-trial/","source":"www.israel21c.org","visible":1,"analysis":{"tags":"medical treatment","company":"Bonus BioGroup","layoffs":null,"summary":"Bonus BioGroup, an Israeli company, has reported positive results from a Phase II clinical trial of its drug product MesenCure in treating severe Covid-19 patients. The trial showed a survival rate of 94% among patients treated with MesenCure, with a reduction in hospitalization period and mortality compared to a control group. The treatment was found to be four times more effective than the current standard of care. Bonus BioGroup plans to apply for emergency use approval from regulatory agencies in Europe and the US. The companys success in developing an effective treatment for severely ill Covid-19 patients has positioned it as a leader in the field.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["MesenCure","Covid-19","clinical trial","hospitalization period","mortality rate"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Customers  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"b9CNy8R8woIOeEgXDqSb8X8u41fRdPgf22dS3cFhJZ7lVVKI5ohH1D","news_summary":"Covid drug saves 47 of 50 severe patients in trial","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"62b7933a-fdd6-4e5d-a4b5-4dfa062de8e2","date":"Aug 22, 2021","link":"https://www.globenewswire.com/news-release/2021/08/22/2284394/0/en/Bonus-BioGroup-Receives-Approval-to-Expand-Phase-II-Clinical-Trials-for-its-COVID-19-Treatment-to-Medical-Centers-Across-Israel.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"clinical trials","company":"Bonus BioGroup","layoffs":null,"summary":"Bonus BioGroup, an Israeli biotechnology company, has received approval from the Israeli Ministry of Health to expand its phase II clinical trials for its MesenCure treatment. MesenCure is a cell therapy treatment for severe COVID-19 patients suffering from pneumonia and acute respiratory distress caused by the immune systems hyper-inflammatory response. The expansion of the clinical trials comes as infections and hospitalizations surge due to the Delta variant. The phase I/II trials of MesenCure showed success in treating severe COVID-19 patients, resulting in a decrease in inflammation and improved patient prognosis. The company aims to continue evaluating the efficacy and safety of MesenCure through the phase II trial. MesenCure has potential applications beyond COVID-19 and is forecasted to have a global market exceeding $43 billion by 2026.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["MesenCure","COVID-19","clinical trials","cell therapy","pandemic"],"date_of_event":"2021-08-22","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Customers  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"EDg6LH8CLcRsBgwxGLkIHUg472f0KiXdQc0APxosgTcnwOFfHhw7xA","news_summary":"Bonus BioGroup Receives Approval to Expand Phase-II Clinical Trials for its COVID-19 Treatment to Medical Centers Across Israel","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"878c6cac-8b05-4bd6-bc83-ae7f52161a66","date":"Jul 11, 2021","link":"https://en.globes.co.il/en/article-israeli-co-bonus-biogroup-reports-covid-19-treatment-success-1001377650","source":"en.globes.co.il","visible":1,"analysis":{"tags":"stem cell therapy, clinical trial, Covid-19 treatment","company":"Bonus BioGroup","layoffs":null,"summary":"Israeli biotech company Bonus BioGroup reported positive results from a clinical trial of its stem-cell based product MesenCure for the treatment of severe cases of Covid-19. The trial showed significant improvement in health parameters and respiratory function in ten patients treated with MesenCure. The company is now planning to conduct a trial with 50 additional patients. Bonus BioGroup focuses on stem cell therapies and tissue engineering, with its Covid-19 treatment currently being prioritized in clinical trials.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["stem cell therapy","clinical trial","Covid-19 treatment","improvement in health parameters","respiratory function"],"date_of_event":"July 11, 2021","valuation_amount":"NIS 1.3 billion","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"897LFcy8pN89wle5glaefuPz66uayDYNpDXSYl2WoGRzip8BgnVENP","news_summary":"Bonus BioGroup reports Covid-19 treatment success","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ed23fc76-3358-4e4d-9b8f-784669103001","date":"May 31, 2021","link":"https://www.israel21c.org/israeli-biotech-company-aces-phase-i-covid-cure-trial/","source":"www.israel21c.org","visible":1,"analysis":{"tags":"biotechnology, clinical trial","company":"Bonus BioGroup","layoffs":null,"summary":"Israeli biotechnology company Bonus BioGroup announced positive preliminary results of its Phase I clinical trial for treating severely ill Covid-19 patients. The trial involved treating 10 Covid patients with Bonus BioGroups cell therapy drug candidate, MesenCure, resulting in significant improvements in the patients conditions. The Israeli Health Ministry has approved the transition to Phase II of the trial. MesenCure, consisting of activated mesenchymal stromal cells, aims to reduce lung inflammation and promote lung tissue regeneration. The drug may also be used to treat other respiratory diseases. Additionally, the EXO-CD24 experimental treatment for Covid-19, developed by Dr. Nadir Abir, has also received approval for a Phase II/III trial.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Covid-19 treatment","Phase I clinical trial","MesenCure","Israeli Health Ministry","EXO-CD24"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"57iz5IV5aGTWLH9H9OGQff0F3x22r0dNHBc2cByuVdJyPywcN2bjgx","news_summary":"Israeli biotech company aces Phase I Covid cure trial","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"aaf567fd-2dba-42e0-8223-5a734fe812e4","date":"Mar 17, 2021","link":"https://trailer.web-view.net/Links/0X911D6AE7ECAA6EB8B63DDCAD551CBDA19457AA69384F09023F557F0AA605740EDE93858D3333075CDEA6F1280BF246AE5F11A637F1DA12712272BDDA84D40D37171E2D28B793254C.htm","source":"trailer.web-view.net","visible":1,"analysis":{"tags":"medical technology","company":"בונוס ביוגרופ","layoffs":null,"summary":"Israeli biomed company, Bonus BioGroup, has been granted a patent for the development of an artificial blood vessel network to improve the integration of lab-grown organs in the body. The companys stock jumped 4% on the Tel Aviv Stock Exchange, with a valuation of 1.4 billion shekels.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["medical technology","artificial organs","blood vessels","stem cells","tissue engineering"],"date_of_event":"March 17, 2021","valuation_amount":"1.4 billion shekels","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"vYFnk3Fh7fWBRhmNiEzO7mhAskyvNI8Oeoib5d3UxKHvJogUiUrK6d","news_summary":"בונוס ביוגרופ רשמה פטנט על פיתוח רשת כלי דם מלאכותית; המניה מזנקת ב-4%","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"2a00a5c8-e4e5-4489-910a-2298329fb4b9","date":"Jan 19, 2021","link":"https://www.sponser.co.il/Article.aspx?_atscid=7_134353_204082920_1736202_0_Txtetaxjxdshwhus8sp&ArticleId=103443","source":"www.sponser.co.il","visible":1,"analysis":{"tags":"Healthcare, Drug Development","company":"בונוס ביוגרופ","layoffs":"N/A","summary":"Israeli company Bonus Biogroup has received approval from the Ministry of Health to conduct a phase 2 clinical trial of its drug, MesenCure, for the treatment of acute and life-threatening respiratory distress in COVID-19 patients. The trial will be conducted at the Rambam Health Care Campus in Haifa and will include up to 60 patients. The drugs efficacy comes from the targeted operation of mesenchymal cells, which make up the drug, through a unique combination of biological and physical growth conditions. The company estimates that MesenCure could be used to treat a wide range of indications, including lower respiratory tract inflammation, asthma, and obstructive pulmonary disease.","partners":"Ministry of Health, Rambam Health Care Campus","customers":"N/A","investors":"N/A","confidence":8,"key_topics":"Drug Development, Clinical Trials, Health Ministry Approval, Respiratory Inflammation Treatment, COVID-19","date_of_event":"N/A","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":"Investment, Expand","acquisition_amount":"N/A","structuredIssuesShow":"#Investment, Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Fpd9cBRP5Rj4vsyc7tn1sSIEGHGhRsDRD0XIY5sxUtbccYq05v1y5P","news_summary":"בונוס ביוגרופ מתחילה ניסוי קליני בחולי קורונה","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ef6df64f-3ae7-405c-ad55-7e33636c04c9","date":"Jan 4, 2021","link":"https://www.prnewswire.com/il/news-releases/wize-pharma-receives-bonus-biogroup-shares-from-escrow-and-additional-bonus-biogroup-shares-totaling-1-3-million-301200230.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"strategic transaction","company":"Wize Pharma, Inc.","layoffs":null,"summary":"Wize Pharma, Inc. has completed a strategic transaction with Bonus BioGroup Ltd., a biotechnology company. The transaction involved the release of Bonus shares and funds from escrow to Wize. In consideration, Wize received additional Bonus shares worth approximately $1.3 million. The completion of this transaction strengthens Wizes balance sheet and enhances shareholder value. Wize is a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders.","partners":null,"customers":null,"investors":"Bonus BioGroup Ltd.","confidence":9,"key_topics":["Share Purchase Agreement","Bonus BioGroup","Nasdaq Milestone","Balance sheet","Cosmos Capital"],"date_of_event":"2020-12-29","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Acquisition"],"acquisition_amount":null,"structuredIssuesShow":"#Acquisition","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"OqmisEMEzfM7Bf1heazcLKV6qq6EwURE6rMcSaXErI9aDuFt1uvksb","news_summary":"Wize Pharma Receives Bonus BioGroup Shares from Escrow and Additional Bonus BioGroup Shares Totaling $1.3 Million","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"1405aaa1-f3b6-43d8-ac1e-d9b1a1af6366","date":"May 13, 2020","link":"http://www.xinhuanet.com/english/2020-05/13/c_139051608.htm","source":"www.xinhuanet.com","visible":1,"analysis":{"tags":"drug development","company":"Bonus BioGroup","layoffs":null,"summary":"Israeli biotech company Bonus BioGroup has successfully completed trials of a new drug called MesenCure for novel coronavirus. The drug, developed for the treatment of respiratory distress in coronavirus and pneumonia patients, showed promising results in preclinical trials on model animals. The company is now awaiting governmental approval to conduct trials on coronavirus patients. MesenCure consists of stem cells taken from a healthy donors fat tissue, which are transmitted to the patient by blood transfusion to reduce inflammation in the lung tissue and help restore it. The drug was able to reduce 47 percent of the fluid accumulated in the animals lungs.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["drug","coronavirus","respiratory distress","preclinical trials","stem cells"],"date_of_event":"2020-05-12","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"3foq9k28UWxXFNLwTq1mefm46ZEAjSk7khOJlZ0IhxPe47rooaZbA4","news_summary":"Israeli biotech company successfully tests COVID-19 drug: local media","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"a81becf7-3665-42b6-a82e-8ba0e02e0e00","date":"Apr 21, 2020","link":"https://www.prnewswire.com/news-releases/wize-pharmas-strategic-transaction-partner-bonus-biogroup-initiates-preclinical-study-for-treatment-of-respiratory-distress-in-covid-19-patients-301044348.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"biopharmaceutical, clinical-stage, ophthalmic disorders","company":"Wize Pharma, Inc.","layoffs":null,"summary":"Wize Pharma announced that Bonus BioGroup has initiated a preclinical study of its drug product candidate MesenCure, which is developed to potentially treat respiratory distress and pneumonia caused by COVID-19 or other viruses. MesenCure consists of activated mesenchymal stromal cells (MSCs) that are expected to reduce inflammation and alleviate respiratory symptoms. Bonus BioGroup has reported that preliminary efficacy data from the study are expected in May 2020. MesenCure may also be useful for treating other respiratory indications. Wize Pharma owns 8.9% of Bonus BioGroups equity securities. Bonus BioGroup is an Israeli biotechnology company focused on healing severe bone defects. Wize Pharma is a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders.","partners":"Bonus BioGroup","customers":null,"investors":null,"confidence":8,"key_topics":["MesenCure","respiratory distress","pneumonia","inflammatory diseases","lower respiratory tract infections"],"date_of_event":"April 21, 2020","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"sZZVCtXFNikwwpc1GMYsgxhgjKfMyU9ArdWDSgAlCaVYFSjdOtNSNt","news_summary":"Wize Pharma's Strategic Transaction Partner Bonus Biogroup Initiates Preclinical Study for Treatment of Respiratory Distress in COVID-19 Patients","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"daece9ba-9f48-4562-bdd0-eceda1723fa7","date":"Feb 20, 2019","link":"https://nocamels.com/2019/02/world-1st-patient-lab-grown-bone-implant-israman-triathlon/","source":"nocamels.com","visible":1,"analysis":{"tags":"medical technology","company":"Bonus BioGroup","layoffs":null,"summary":"Israeli biotechnology company Bonus BioGroup has developed a revolutionary technology called BonoFill, a tissue-engineered bone graft made from a patients own cells. The process involves extracting fat tissue from the patient, isolating the stem cells, and growing them in a lab until the tissue becomes solid. The hardened bone tissue is then injected back into the patients body. The technology has been successfully used to replace a missing section of a patients shinbone, allowing him to participate in an Israman triathlon. Bonus BioGroup is currently conducting clinical trials for maxillofacial and orthopedic indications. The company also plans to develop products for other tissues such as cartilage and fat tissue.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["lab-grown bone implant","BonoFill","tissue-engineered bone graft","clinical trial","orthopedic surgery"],"date_of_event":"2019-01-01","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$5 million","structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"LAWa2xDwGednWM2TBOTLBTqvmTsx3tduTYcf9vSJgDhKM15sCzcnDH","news_summary":"World's 1st Patient With Lab-Grown Bone Implant Competes In Israman Triathlon","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"85578717-2da0-48cf-a7f8-4a5d81425f72","date":"Aug 8, 2018","link":"http://allbizportal.com/bonus-1b7-3bok/index.php/press-room/press-releases?id=75","source":"allbizportal.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"jQqRk999fy3U4EYENVlkJuZNKgdE0BDngZzi3fcJV1uVt62TyYi6ST","news_summary":"http://allbizportal.com/bonus-1b7-3bok/index.php/press-room/press-releases?id=75","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"61e9f5d2-7188-44cb-a249-b3aff5a02860","date":"Mar 12, 2018","link":"https://www.calcalistech.com/ctech/articles/0,7340,L-3733853,00.html","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"biotechnology, clinical trial","company":"Bonus Biogroup Ltd.","layoffs":null,"summary":"Israel-based biotechnology company Bonus Biogroup has launched a new clinical trial to test its injectable bone grafts in patients suffering from critical bone loss. The company uses fat tissue collected from patients to create an injectable mixture containing bone-forming cells, growth stimulating factors, and scaffolding material. The grafts are autologous, meaning they have a low risk of rejection and do not require invasive surgery. The announcement of the clinical trial caused Bonus Biogroups stock to rise by 11% on the Tel Aviv Stock Exchange, giving the company a market cap of over NIS 500 million ($145 million). Bonus Biogroup is also in the process of listing on a stock exchange in the US.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["bone grafts","clinical trial","injectable mixture","autologous grafts","stock exchange listing"],"date_of_event":"12.03.18","valuation_amount":"$145 million","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Investment","Public Trading"],"acquisition_amount":null,"structuredIssuesShow":"#Customers  #Investment  #Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"nvqVOH6UpOTv9911WtLasozglXc1AYvN35DHVxBzSRLfGlHtJXnBHr","news_summary":"Company that Develops Injectable Bone Grafts Expands Clinical Trial","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"b951b88b-0f3f-4153-bb00-b58400867da3","date":"Feb 13, 2018","link":"https://www.timesofisrael.com/israeli-biotech-company-successfully-grows-bones-in-lab/","source":"www.timesofisrael.com","visible":1,"analysis":{"tags":"Biotech, Bone Regrowth","company":"Bonus BioGroup","layoffs":"Not mentioned","summary":"Bonus BioGroup, a biotech company based in Haifa, is entering the second trial of a clinical study that aims to regrow bones in a lab. The first trial, which began four years ago and included 32 patients, was completed successfully. The process involves using liposuction to retrieve fat cells from the body, from which damage-controlling cells are isolated and grown in a bioreactor. The new bone is then injected back into the patient. The company expects the bone regenerating treatment to finish its trials, gain FDA approval and hit the market in three to four years.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Bone Regrowth","Clinical Trials","Investment","Biotech","Healthcare"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$20 million","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"lUQmZ2uWGOAunffBvkHDRITwxqEpbeedrlNA6TpcDIz5YEs9Rc0s2y","news_summary":"Israeli biotech company successfully grows bones in lab","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"f51b3468-c58b-4ba3-a24f-91954e309d06","date":"Dec 22, 2017","link":"http://www.ibtimes.com/doctors-conduct-first-ever-science-fiction-bone-regrowth-surgery-patient-2632104","source":"www.ibtimes.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"WEeYm0jrWcaZbwsyVD3pPheQSfAkBIIDLIE9dZVqPFvBwrn2CHguWB","news_summary":"Doctors Conduct First-Ever 'Science Fiction' Bone Regrowth Surgery On Patient","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"59a7996f-9761-462e-b16c-00133488c3d1","date":"Dec 20, 2017","link":"http://www.globes.co.il/en/article-successful-bone-implant-boosts-bonus-biogroup-1001216426","source":"www.globes.co.il","visible":1,"analysis":{"tags":"Medical Innovation, Stock Trading","company":"Bonus BioGroup Ltd.","layoffs":"N/A","summary":"Shares in stem cell company Bonus BioGroup were temporarily halted after the first patient successfully underwent a bone implant developed by the company. The halt in trading is an unusual step for medical companies, even those with innovative products. Following the announcement and subsequent media coverage, Bonus BioGroups shares rose 15% when trading resumed, pushing its market cap up to NIS 400 million. The company still has a long way to go before its product reaches the market and is successful.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Stem Cell Technology","Bone Implant","Clinical Trial","Stock Trading","Market Potential"],"date_of_event":"December 20, 2017","valuation_amount":"NIS 400 million","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Public Trading"],"acquisition_amount":"N/A","structuredIssuesShow":"#Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"SrK2JzBeL4kzdXiC6myfdzFitMoRrgsXFFEI6zQNOfQavWpqHqDsri","news_summary":"Successful bone implant boosts Bonus BioGroup","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"1adead5c-f51d-45ab-acce-380becae9fc3","date":"Aug 17, 2017","link":"https://www.israel21c.org/in-world-first-israeli-man-gets-lab-grown-bone-tissue-injected-in-arm/","source":"www.israel21c.org","visible":1,"analysis":{"tags":"medical technology","company":"Bonus BioGroup","layoffs":null,"summary":"Bonus BioGroup, a medical technology company based in Haifa, has successfully transplanted semi-liquid live human bone tissue grown in a lab into a patients arm. The procedure was part of an early-stage clinical trial of the companys tissue-engineering technology. Bonus BioGroup previously announced successful results of a similar trial in which bone tissue grown from a patients own fat cells was injected into their jaws. The companys technique involves growing bone under sterile laboratory conditions from stem cells in fat tissue taken from the patient. Bonus BioGroup raised $9 million in a private offering investment last April. The injectable bone-graft technique is seen as a major improvement over traditional bone grafts.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["tissue-engineering","bone transplant","clinical trial","stem cells","medical technology"],"date_of_event":"Not mentioned","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$9 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"HBViSnbhM9Dr4NS9E8xU765RCzmfFenQsD0G1n5Gs7Ay7Ny3Y3oCHA","news_summary":"In world first, Israeli man gets lab-grown bone tissue injected in arm","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"56489335-25d0-4cfb-b3d3-e6227fc59aaf","date":"Apr 7, 2014","link":"http://www.globes.co.il/en/article-trial-start-boosts-bonus-biogroup-1000930346","source":"www.globes.co.il","visible":1,"analysis":{"tags":"clinical trial","company":"Bonus Biogroup Ltd.","layoffs":null,"summary":"Bonus Biogroup Ltd., a company that produces bone grafts from stem cells, has started a clinical trial of jawbone grafts. The trials interim results are expected in four months. The companys share price rose following the announcement. Bonus Biogroup uses its proprietary technology to encourage cells from fatty tissue to differentiate into bone cells for grafts. The company plans to complete the trial within a year and needs to raise $5-7 million to move forward with trials for this and other products.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["bone grafts","stem cells","clinical trial","production center","financial report"],"date_of_event":"April 7, 2014","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ZdIK8OyatKwrOOHrOAWWcNitLmkysNcJV1zbCat6rKeCfgwtDsjUCO","news_summary":"Trial start boosts Bonus BioGroup","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ad10f946-501f-440d-b596-1f13893b2a1c","date":"Jun 25, 2012","link":"http://www.israel21c.org/israeli-company-grows-new-bones-from-fat/","source":"www.israel21c.org","visible":1,"analysis":{"tags":"regenerative medicine","company":"Bonus Biogroup","layoffs":null,"summary":"Bonus Biogroup, an Israeli regenerative medicine company, has developed a method to grow human bone from a patients own fat. Clinical trials are set to begin within the next year in Europe or Israel for various applications, including dental surgery and replacing lost bone tissue. The companys innovative technology involves extracting stem cells from fat tissues and growing them into real human bone on a scaffold in a bioreactor. The process allows for bone to be grown outside the body and used in reconstructive surgery. The impact of this technology is growth-positive for Bonus Biogroup, as it has the potential to revolutionize bone transplantation and dental implants. The company plans to expand its staff and hopes to fast-track through clinical trials in about three years. The technology is expected to cost several thousand dollars per bone graft, with most of the cost covered by healthcare insurance.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["regenerative medicine","bone growth","clinical trials","stem cells","bioreactor"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"vFuDmQwMqtkTzXRoyyP6ClK9tVRmjPMpFGaiPFwkBlPr1Lo3lz1YVn","news_summary":"Israeli company grows new bones from fat","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":38,"techcommunityinvolvement":null,"mediagallery":[{"id":"ee74bf75-1ae5-475f-be43-4675bed23511","timestamp":"2020-02-25 12:57:26.000000","resources_type":2,"resources_title":"","resources_file_name":"A4qH9EzoY7I","alt":"","imageurl":"https://img.youtube.com/vi/A4qH9EzoY7I/0.jpg","url":"http://youtu.be/A4qH9EzoY7I"},{"id":"457efe2e-8a77-401e-929c-573e1511b5bc","timestamp":"2019-05-23 13:15:09.000000","resources_type":2,"resources_title":"Bonus BioGroup","resources_file_name":"NStGjzE37jw","alt":"Bonus BioGroup logo","imageurl":"https://img.youtube.com/vi/NStGjzE37jw/0.jpg","url":"http://youtu.be/NStGjzE37jw"}],"tags":["biotechnology","regenerative-medicine","bone","medical-technologies","tissue-regeneration","3d-technology","cell-therapy","stem-cells","personalized-medicine","orthopedics"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B"],"productstage":"Clinical Trial","products":["BonoFill","MesenCure"],"geomarkets":["Global"],"targetmarkets":[],"marketcapital":77183093,"marketcapitaldate":"2025-11-01T14:03:58.000Z","funding":{"investors":2,"lastfunding":"$5M","totalrounds":5,"fundingstage":"Public","totalfunding":"$25.6M","publicinvestors":2,"lastpublicfunding":5000000,"totalpublicrounds":5,"totalpublicfunding":25600000},"team":[{"name":"Yossi Rauch","email":"yrauch@bonus-bio.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoKK36ssLDA","bounced":true,"claimed":0,"founder":0,"urlname":"yossi-rauch","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICg4onplAoM","position":"Executive Chairman of the Board","last_name":"Rauch","claimtoken":"DdwwqTZ19YGhvL8irMxXHDl13ABld1mwHavtjuCfp4mHOg3ZtVKiVP","first_name":"Yossi","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/yossi-rauch-b389a053/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-11-16 14:11:23.000000","initials":"YR","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Shai Meretzki","email":"shaime@bonus-bio.com","phone":"0505277781","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgLHfosMIDA","bounced":false,"claimed":0,"founder":1,"urlname":"shai-meretzki-2","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICAvozRywgM","position":"Founder, CEO & President","last_name":"Meretzki","claimtoken":"WTUmxyQmxCmpqgUc6p4zXmbJRjl3VVdnWyAxnWRrQh4WBP2Qk4z3Zs","first_name":"Shai","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/shai-meretzki-7265b811/","unsubscribed":false,"is_activeuser":0,"additionalemail":"smerezky@bonus-bio.com","claimedemaildate":"2022-11-16 14:11:05.000000","initials":"SM","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Prof. Avinoam Kadouri (late)","email":"","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoOLwqZsKDA","bounced":false,"claimed":0,"founder":1,"urlname":"prof-avinoam-kadouri-late","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICgoqmmiwoM","position":"Founder (No longer with the company)","last_name":"Kadouri (late)","claimtoken":"115ef76e0fa0b583aefd32c0365880488fea71fc95de6fb8bef8594eef1ddb53","first_name":"Prof. Avinoam","picturekey":null,"claimeddate":null,"linkedinurl":null,"unsubscribed":false,"is_activeuser":1,"additionalemail":"akadouri@bonus-bio.com","claimedemaildate":"2020-02-25 12:58:31.000000","initials":"PK","pictureurl":"/assets/empty-state.svg","linkedin-display":"none","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Yoni Livne","email":"yonatan.akbali@gmail.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAwOa--OEKDA","bounced":false,"claimed":1,"founder":0,"urlname":"yoni-livne-1","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICAscPwlAgM","position":"CFO","last_name":"Livne","claimtoken":"9b65dca1df467e03ad294f388cac37dc8297b8a72926cb2b62e6aecb51f5c12e","first_name":"Yoni","picturekey":"$b5ondHNmYK7Mo2Sd38INewXcaZFOJbP9EmjMKbjBcozAgYk3PTZOzk","claimeddate":"2016-10-05","linkedinurl":"https://www.linkedin.com/in/yoni-livne-27bb5071","unsubscribed":false,"is_activeuser":0,"additionalemail":"yonatan.akbali@gmail.com","claimedemaildate":"2016-10-05 12:21:03.000000","initials":"","pictureurl":"https://storage.googleapis.com/clean-finder-353810/$b5ondHNmYK7Mo2Sd38INewXcaZFOJbP9EmjMKbjBcozAgYk3PTZOzk","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Vered Kivity","email":"veredk@bonus-bio.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4KuY-MgLDA","bounced":true,"claimed":0,"founder":0,"urlname":"vered-kivity","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDg6468wgkM","position":"Head Of Regulatory Affairs","last_name":"Kivity","claimtoken":"BfygcR8yKNNYsX2896wyyPDNczzCGnwZMzb5G2hT367nVPaAkSvaYO","first_name":"Vered","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/vered-kivity-505b0a7/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-11-16 14:11:46.000000","initials":"VK","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Digital Health and Medical Technologies","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgLHD0KwIDA","fullname":"Sharon Shapira"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgMGgoMMJDA","fullname":"Yanina Wainscheinker"},"biverifydate":"2020-06-03T00:00:00.000Z","crunchbaseid":"bonus-biogroup","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":"Jenny Sotnik-Talisman","creator_email":"genys30@yahoo.com","createdate":"2014-07-23T00:00:00.000Z","biverification":"Yanina Wainscheinker","sectorverification":"Sharon Shapira","affiliatedOrganizations":null,"timeline":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCr6O_5Cgw","date":"Feb 2021","amount":"$5M","source":"https://www.linkedin.com/posts/bonus-biogroup_biotechnology-celltherapy-tissueengineering-activity-6761921353990840320-ddU0","eventtype":"FundingRoundEvent","investment":[{"name":"SIBF VC","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/sibf-vc","logokey":"$QKiD0aOkPUkeEqTxuiaxGwOaFb1FValjsfaaKe1Q5SdT5mmqyamsdw","tagline":null,"urlname":"/investor_page/sibf-vc","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4L7Wg5ELDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"aef9b53c-f81d-4724-bb6d-a6094aed0c53","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$QKiD0aOkPUkeEqTxuiaxGwOaFb1FValjsfaaKe1Q5SdT5mmqyamsdw","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":5000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCrq8nwCQw","date":"Jan 2021","amount":"$14M","source":"https://maya.tase.co.il/reports/details/1350413/2/0","eventtype":"FundingRoundEvent","investment":[{"name":"Undisclosed Investor(s)","type":"Investor","amount":0,"hidden":false,"country":"Europe","fullurl":"/investor_page/undisclosed-investor-s","logokey":null,"tagline":"","urlname":"/investor_page/undisclosed-investor-s","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3CCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"378fa826-b873-4ff2-a6f2-e6fa9605c905","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":14000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODkyenHCgw","date":"Sep 2018","amount":"$5M","source":"http://www.bonus-bio.com/index.php/news-media/press-releases/item/28-bonus-biogroup-raises-investment-in-the-amount-of-nis-18-million-usd-5-million-at-a-price-of-60-agorot-per-share","eventtype":"FundingRoundEvent","investment":[{"name":"Undisclosed Investor(s)","type":"Investor","amount":0,"hidden":false,"country":"Europe","fullurl":"/investor_page/undisclosed-investor-s","logokey":null,"tagline":"","urlname":"/investor_page/undisclosed-investor-s","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3CCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"784636c0-92b3-44a7-9668-86adf4cf5665","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":5000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODY5ZH9CAw","date":"Jan 2015","amount":"$1.6M","source":"Added by Daniela Gehtaman","eventtype":"GrantEvent","granttype":1,"investment":[{"name":"Office of the Chief Scientist","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/office-of-the-chief-scientist","logokey":null,"tagline":"","urlname":"/investor_page/office-of-the-chief-scientist","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEv8qRCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"db5e905a-3f90-4df6-8e50-b2d838b835e5","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":1600000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCwlbKPCQw","date":"Feb 2012","amount":"Undisclosed","source":"","ticker":"BONS","eventtype":"POEvent","valuation":"Undisclosed","investment":[],"capitalraised":"Undisclosed","stockexchange":"TASE","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCot526Cgw","stockexchange_logokey":"$lbzaT2u1ZZsaxZoI8dlPGaVypdtKjf7mkYzKR0EFwkK0sKlf9u3hyJ","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$lbzaT2u1ZZsaxZoI8dlPGaVypdtKjf7mkYzKR0EFwkK0sKlf9u3hyJ","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":null,"valuationnumber":null}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"10/1981","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Bonus BioGroup","logourl":"https://storage.googleapis.com/clean-finder-353810/$jMMfmIzlohFeW1U54Fj6ANul5oWkmryUpVqntHKkYKwX8r9hGsKwKJ","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$jMMfmIzlohFeW1U54Fj6ANul5oWkmryUpVqntHKkYKwX8r9hGsKwKJ","seoabout":"Bonus BioGroup is a product-focused biotechnology company applying proprietary technology to supply tissue-regenerating, viable bone grafts. The company de...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":5,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Cells","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Patients","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Biotechnology","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Patients#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA>Cells#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|2:>TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA/Cells#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Patients#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drugs Discovery & Development","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Healthcare","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare","children":[{"title":"Patients","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Patients"},{"title":"Providers","key":"0-0-0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Providers"}]},{"title":"Life Sciences","key":"0-0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Biotechnology","key":"0-0-1-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Biotechnology"}]}]}],"coreTechnology":[{"title":"Biologicals","key":"0-0","path":"TechnologyClassificationModel>Biologicals","children":[{"title":"Cells","key":"0-0-0","path":"TechnologyClassificationModel>Biologicals>Cells"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Cells","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Patients","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Biotechnology","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drugs Discovery & Development"],"coreTechnology":["Biologicals","Cells"],"targetCustomer":["Healthcare & Life Sciences","Healthcare","Patients","Providers","Life Sciences","Biotechnology"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"inline","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCwlbKPCQw","date":"Feb 2012","amount":"Undisclosed","source":"","ticker":"BONS","eventtype":"POEvent","valuation":"Undisclosed","investment":[],"capitalraised":"Undisclosed","stockexchange":"TASE","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCot526Cgw","stockexchange_logokey":"$lbzaT2u1ZZsaxZoI8dlPGaVypdtKjf7mkYzKR0EFwkK0sKlf9u3hyJ","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$lbzaT2u1ZZsaxZoI8dlPGaVypdtKjf7mkYzKR0EFwkK0sKlf9u3hyJ","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":null,"valuationnumber":null}],"privateequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCr6O_5Cgw","date":"Feb 2021","amount":"$5M","source":"https://www.linkedin.com/posts/bonus-biogroup_biotechnology-celltherapy-tissueengineering-activity-6761921353990840320-ddU0","eventtype":"FundingRoundEvent","investment":[{"name":"SIBF VC","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/sibf-vc","logokey":"$QKiD0aOkPUkeEqTxuiaxGwOaFb1FValjsfaaKe1Q5SdT5mmqyamsdw","tagline":null,"urlname":"/investor_page/sibf-vc","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4L7Wg5ELDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"aef9b53c-f81d-4724-bb6d-a6094aed0c53","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$QKiD0aOkPUkeEqTxuiaxGwOaFb1FValjsfaaKe1Q5SdT5mmqyamsdw","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":5000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCrq8nwCQw","date":"Jan 2021","amount":"$14M","source":"https://maya.tase.co.il/reports/details/1350413/2/0","eventtype":"FundingRoundEvent","investment":[{"name":"Undisclosed Investor(s)","type":"Investor","amount":0,"hidden":false,"country":"Europe","fullurl":"/investor_page/undisclosed-investor-s","logokey":null,"tagline":"","urlname":"/investor_page/undisclosed-investor-s","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3CCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"378fa826-b873-4ff2-a6f2-e6fa9605c905","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":14000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODkyenHCgw","date":"Sep 2018","amount":"$5M","source":"http://www.bonus-bio.com/index.php/news-media/press-releases/item/28-bonus-biogroup-raises-investment-in-the-amount-of-nis-18-million-usd-5-million-at-a-price-of-60-agorot-per-share","eventtype":"FundingRoundEvent","investment":[{"name":"Undisclosed Investor(s)","type":"Investor","amount":0,"hidden":false,"country":"Europe","fullurl":"/investor_page/undisclosed-investor-s","logokey":null,"tagline":"","urlname":"/investor_page/undisclosed-investor-s","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3CCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"784636c0-92b3-44a7-9668-86adf4cf5665","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":5000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODY5ZH9CAw","date":"Jan 2015","amount":"$1.6M","source":"Added by Daniela Gehtaman","eventtype":"GrantEvent","granttype":1,"investment":[{"name":"Office of the Chief Scientist","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/office-of-the-chief-scientist","logokey":null,"tagline":"","urlname":"/investor_page/office-of-the-chief-scientist","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEv8qRCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"db5e905a-3f90-4df6-8e50-b2d838b835e5","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":1600000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"merger_acquisitions":[],"others":[]}}